Memo Therapeutics secures $15.5m in Series B to propel antibody development for COVID-19 and BK virus treatment

Memo Therapeutics, a Swiss biotech company, has successfully raised CHF 14 million (approximately $15.56 million) in a Series B financing round to accelerate the clinical ... Read More